摘要: ▴ Docetaxel and cisplatin are well established antineoplastic agents with activity against NSCLC. The combination exhibited additive cytotoxic human NSCLC cell lines in vitro.
springer.com
sci-hub.se 参考文章(22)
René Bruno, Nicole Vivier, Christine Veyrat-Follet, Guy Montay, Gerald R. Rhodes, Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel Investigational New Drugs. ,vol. 19, pp. 163- 169 ,(2001) , 10.1023/A:1010687017717
M J Millward, J Zalcberg, J F Bishop, L K Webster, A Zimet, D Rischin, G C Toner, J Laird, W Cosolo, M Urch, R Bruno, C Loret, R James, C Blanc, Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 15, pp. 750- 758 ,(1997) , 10.1200/JCO.1997.15.2.750
George R. Simon, Paul A. Bunn, Taxanes in the Treatment of Advanced (Stage III and IV) Non-small Cell Lung Cancer (NSCLC): Recent Developments Cancer Investigation. ,vol. 21, pp. 87- 104 ,(2003) , 10.1081/CNV-120005919
J Zalcberg, M Millward, J Bishop, M McKeage, A Zimet, G Toner, M Friedlander, C Barter, D Rischin, C Loret, R James, N Bougan, J Berille, Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 16, pp. 1948- 1953 ,(1998) , 10.1200/JCO.1998.16.5.1948
Alison M. Comer, Karen L. Goa, Docetaxel: a review of its use in non-small cell lung cancer. Drugs & Aging. ,vol. 17, pp. 53- 80 ,(2000) , 10.2165/00002512-200017010-00004
Corey J. Langer, Mark Vangel, Joan Schiller, David R. Harrington, Alan Sandier, Chandra Belani, David Johnson, O-49 Age-specific subanalysis of ECOG 1594: Fit elderly patietns (70–80 yrs) with NSCLC do as well as younger patients (<70) Lung Cancer. ,vol. 41, pp. S17- ,(2003) , 10.1016/S0169-5002(03)91707-7
T Le Chevalier, A Monnier, J.Y Douillard, P Ruffie, X.S Sun, L Belli, N Ibrahim, N Bougon, J Bérille, Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. European Journal of Cancer. ,vol. 34, pp. 2032- 2036 ,(1998) , 10.1016/S0959-8049(98)00287-1
V. Georgoulias, G. Samonis, E. Papadakis, A. Alexopoulos, X. Tsiafaki, A. Rapti, M. Veslemes, Th. Grigoratou, Ph. Palamidas, Ch. Kouroussis, D. Mavroudis, S. Kakolyris, Th. Giannakakis, J. Vlachonikolis, Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial Lung Cancer. ,vol. 34, pp. 47- 51 ,(2001) , 10.1016/S0169-5002(01)00417-2
Chandra P. Belani, Frank V. Fossella, O-51 Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCB) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small cell lung cancer (NSCLC): analyses in elderly patients Lung Cancer. ,vol. 41, pp. S18- ,(2003) , 10.1016/S0169-5002(03)91709-0
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954